MiNK Therapeutics Inc

MiNK Therapeutics’ new accounting hire signals stronger financial stewardship and partnership‑driven growth, positioning the biopharma for better reimbursement and investor confidence.

MiNK Therapeutics insider trading: board member Ryan Barbara sold 1,500 shares at $10–$15, raising valuation questions amid a 2.48% weekly gain and 40% yearly rally.